

## 2021 Current Fiscal Year Report: Advisory Committee on Breast Cancer in Young Women

Report Run Date: 05/10/2021 08:59:03 AM

<b>1. Department or Agency</b>		<b>2. Fiscal Year</b>	
Department of Health and Human Services		2021	
<b>3. Committee or Subcommittee</b>		<b>3b. GSA Committee No.</b>	
Advisory Committee on Breast Cancer in Young Women		73636	
<b>4. Is this New During Fiscal Year?</b>	<b>5. Current Charter</b>	<b>6. Expected Renewal Date</b>	<b>7. Expected Term Date</b>
No	06/17/2020	06/17/2022	
<b>8a. Was Terminated During FiscalYear?</b>	<b>8b. Specific Termination Authority</b>	<b>8c. Actual Term Date</b>	
No			
<b>9. Agency Recommendation for Next FiscalYear</b>	<b>10a. Legislation Req to Terminate?</b>	<b>10b. Legislation Pending?</b>	
Continue	Not Applicable	Not Applicable	
<b>11. Establishment Authority</b> Statutory (Congress Created)			
<b>12. Specific Establishment Authority</b>	<b>13. Effective Date</b>	<b>14. Committee Type</b>	<b>14c. Presidential?</b>
Section 399NN of the of the Public Health Service Act	03/23/2010	Continuing	No
<b>15. Description of Committee</b> Other Committee			
<b>16a. Total Number of Reports</b>	No Reports for this FiscalYear		
<b>17a. Open Meetings and Dates</b>	<b>17b. Closed Meetings and Dates</b>	<b>17c. Partially Closed Meetings and Dates</b>	<b>17d. Total Meetings and Dates</b>
No Meetings			

	Current FY	Next FY
<b>18a(1). Personnel Pmts to Non-Federal Members</b>	\$0.00	\$0.00
<b>18a(2). Personnel Pmts to Federal Members</b>	\$0.00	\$0.00
<b>18a(3). Personnel Pmts to Federal Staff</b>	\$0.00	\$0.00
<b>18a(4). Personnel Pmts to Non-Member Consultants</b>	\$0.00	\$0.00
<b>18b(1). Travel and Per Diem to Non-Federal Members</b>	\$0.00	\$0.00
<b>18b(2). Travel and Per Diem to Federal Members</b>	\$0.00	\$0.00
<b>18b(3). Travel and Per Diem to Federal Staff</b>	\$0.00	\$0.00
<b>18b(4). Travel and Per Diem to Non-member Consultants</b>	\$0.00	\$0.00
<b>18c. Other(rents,user charges, graphics, printing, mail, etc.)</b>	\$0.00	\$0.00

<b>18d. Total</b>	\$0.00	\$0.00
<b>19. Federal Staff Support Years (FTE)</b>	0.00	0.00

**20a. How does the Committee accomplish its purpose?**

The committee is authorized to recommend evidence-based initiatives for the purposes of advancing understanding and awareness of breast cancer among young women (particularly those at heightened risk for developing breast cancer); to establish and conduct public and health care professional education activities; to conduct prevention research; and to support the dissemination of evidence-based age appropriate messages and materials.

**20b. How does the Committee balance its membership?**

Membership includes expertise in the fields of breast cancer, prevention, early detection, diagnosis, public health, social marketing, genetic testing and counseling, treatment, rehabilitation, palliative care, and survivorship or in related disciplines with a specific focus on young women. The committee also includes ex-officio representatives from the National Cancer Institute; Department of Defense; Indian Health Service; Agency for Healthcare Research and Quality; Health Resources and Services Administration; and the US Department of Health and Human Services, Office of Womens Health. The committee has twelve females and seven ethnic/racial minority representatives.

**20c. How frequent and relevant are the Committee Meetings?**

Meetings are held one to two times per year, which are relevant to items outlined in the committee's charter. This includes establishing and conducting public and health care professional education activities, conducting prevention research, and supporting the dissemination of evidence-based age appropriate messages and materials. However, if the need arises, the committee will convene a meeting to meet the needs of the committee/agency.

**20d. Why can't the advice or information this committee provides be obtained elsewhere?**

The Advisory Committee on Breast Cancer in Young Women shall provide advice and guidance to the Secretary, HHS, the Assistant Secretary for Health, and the Director, CDC, regarding the formative research, development, implementation and evaluation of evidence-based activities designed to prevent breast cancer and promote the early detection and support of young women who develop the disease. The advice provided by the Committee will assist in ensuring scientific quality, timeliness, utility, and dissemination of credible appropriate messages and resource materials.

## 20e. Why is it necessary to close and/or partially closed committee meetings?

N/A

## 21. Remarks

No formal recommendations were made in FY20. This committee does not generate reports. Marisa Weiss served as a special government employee from 9/22/2015 - 4/7/2019. She also served as a representative from 4/8/2019 - 11/30/2022.

## Designated Federal Officer

Jeremy McCallister Public Health Analyst

Committee Members	Start	End	Occupation	Member Designation
Avner, Lindsay	01/18/2017	11/30/2020	Founder and Chairman of the Board	Special Government Employee (SGE) Member
Brown, Susan	04/18/2012	11/30/2020	Managing Director, Community Health	Representative Member
Cerullo, Michele	04/01/2019	11/30/2020	Assistant General Counsel	Special Government Employee (SGE) Member
Chambers, Shonta	11/24/2014	11/30/2020	Executive Vice President, Health Equity	Representative Member
Chism, Lisa	04/04/2019	11/30/2021	Clinical Director	Special Government Employee (SGE) Member
Crollman, Anna	04/08/2019	11/30/2020	Breast Cancer Advocate	Special Government Employee (SGE) Member
Cunningham, Carletta	04/02/2019	11/30/2021	Breast Cancer Survivor	Special Government Employee (SGE) Member
Davidson, Ellyn	01/18/2017	11/30/2020	President, Brogran & Brogan	Special Government Employee (SGE) Member
Dhage, Shubhada	01/20/2017	11/30/2020	Associate Director of Diversity in Cancer Research	Special Government Employee (SGE) Member
Fabiyi, Camille	07/01/2019	06/30/2023	Senior Advisory for Women's Health and Gender Research	Ex Officio Member
Friedman, Susan	01/18/2017	11/30/2021	Executive Director	Representative Member
Hanson, Arin	03/22/2013	11/30/2020	Manager, Young Women's Initiative	Representative Member
Jeady, Myrlene	02/28/2017	11/30/2021	Assistant Professor in Obstetrics and Gynecology	Representative Member
Karmo, Maimah	03/22/2013	11/30/2020	Chief Executive Officer	Representative Member
Lee, Jung-Min	04/25/2014	11/30/2020	Assistant Clinical Investigator, National Institutes of Health	Ex Officio Member
Lin, Kenneth	04/08/2019	11/30/2021	Professor of Family Medicine	Special Government Employee (SGE) Member
Lythcott, Ngina	11/30/2010	11/30/2020	Consultant	Representative Member
Mayo, Rachel	04/17/2018	11/30/2021	Professor, Clemson University	Special Government Employee (SGE) Member
Merschdorf, Jennifer	07/25/2013	11/30/2020	Chief Executive Officer	Representative Member
Sanft, Tara	01/23/2017	11/30/2020	Assistant Professor of Medicine	Special Government Employee (SGE) Member
Saphier, Nicole	05/14/2018	11/30/2022	Director of Breast Imaging, Memorial Sloan-Kettering, Monmouth	Special Government Employee (SGE) Member
Silber, Elana	01/17/2017	11/30/2020	Executive Director	Special Government Employee (SGE) Member
Tannenbaum Turner, Joyce	04/20/2018	11/30/2022	Director, Cancer Genetic Counseling Program, Children's National Medical Center	Special Government Employee (SGE) Member
Thorner, Elissa	04/16/2019	11/30/2021	Director, Breast Cancer Survivorship	Special Government Employee (SGE) Member
Toedt, Michael	05/25/2018	11/30/2022	Chief Medical Officer, Indian Health Service	Ex Officio Member

Torres, Mylin 04/08/2019 11/30/2021 Co-Leader, Cancer Prevention Control Research Program  
Weiss, Marisa 04/08/2019 11/30/2022 President and Founder

Special Government Employee (SGE) Member Representative Member

**Number of Committee Members Listed: 27**

**Narrative Description**

The Advisory Committee on Breast Cancer in Young Women provides advice and guidance to the Secretary, HHS, the Assistant Secretary for Health, and the Director, CDC, regarding the formative research, development, implementation and evaluation of evidence-based activities designed to prevent breast cancer (particularly among those at heightened risk) and promote the early detection and support of young women who develop the disease. The advice provided by the Committee will assist in ensuring scientific quality, timeliness, utility, and dissemination of credible appropriate messages and resource materials.

**What are the most significant program outcomes associated with this committee?**

Checked if Applies

- Improvements to health or safety
- Trust in government
- Major policy changes
- Advance in scientific research
- Effective grant making
- Improved service delivery
- Increased customer satisfaction
- Implementation of laws or regulatory requirements
- Other

**Outcome Comments**

N/A

**What are the cost savings associated with this committee?**

Checked if Applies

- None
- Unable to Determine
- Under \$100,000
- \$100,000 - \$500,000
- \$500,001 - \$1,000,000
- \$1,000,001 - \$5,000,000
- \$5,000,001 - \$10,000,000

Over \$10,000,000  
Cost Savings Other



### **Cost Savings Comments**

Not Applicable

### **What is the approximate Number of recommendations produced by this committee for the life of the committee?**

12

### **Number of Recommendations Comments**

The committee did not put forth formal recommendations in FY20. There were 9 formal recommendations in FY15 and 3 formal recommendations in FY14 for a total of 12 recommendations for the life of the committee.

### **What is the approximate Percentage of these recommendations that have been or will be Fully implemented by the agency?**

75%

### **% of Recommendations Fully Implemented Comments**

9 of 12 recommendations have been fully implemented. They include FY15 Recommendations #1-4, #6 & #9 and all FY14 Recommendations 1-3. In FY20: FY14 Recommendation #2, FY15 Recommendations #6, & #9 which address Patient & Provider communication were completed. CDC funded an effort to identify important health messages and resources needed to facilitate patient/provider dialogue regarding early breast cancer in FY17. In FY18, A Breast Health Education Evaluation occurred where CDC funded a contract to evaluate existing programs which educate Health Care Providers (HCPa) about HBOC and early onset breast cancer. The project was completed and deployed to the public in FY20. Two Continuing Medical Education (CME) Modules including The Educating Medical Providers about Breast Cancer in Young Women: Breast Cancer Risk Factors, Survivorship, and Breast Health contract awarded in FY15 and released in FY17 and The Understanding Early Onset Breast Cancer CME Module in FY20 address FY15 Recommendations #6,#8,#9 & FY14 Recommendation #3. Additionally, in FY20 A Risk Assessment Tool was created and is now available to health care providers on the CDC Division of Cancer Prevention and Control website. Also, resources have been developed for providers and consumers about Direct to Consumer Genetic Testing. CDC continues to expand upon the Bring Your Brave (BYB) Campaign which was most recently funded in FY18- FY20. Bring Your Brave is a large social/digital media campaign launched in 2015 to provide information about breast cancer to women

younger than age 45. The campaign tells real stories about young women whose lives have been affected by breast cancer. These stories about prevention, risk, family history and survivorship bring to life the idea that young women can be personally affected by breast cancer. Through these testimonials, Bring Your Brave aims to inspire young women to learn their risk for breast cancer, talk with their health care provider about their risk, and live a breast healthy lifestyle. The current contract, FY20 ,focuses primarily on HCP education and communication with young women. A project to develop additional video-based training resources for HCPs was funded through the CDC Center for State, Tribal, Local, and Territorial Support (CSTLTS) in FY18 and was completed in FY20. In FY17 CDC implemented the following efforts with regard to recommendations 6 & 8: Doc Styles Survey: CDC implemented a survey about early onset breast cancer and provider behavior on the Doc Styles survey. Data collection was completed in June 2017 and analysis is complete. Bring Your Brave formative research: CDC implemented multiple rounds of formative research to engage with Health Care Providers (HCPs) regarding their breast cancer education needs and resources; findings resulted in the development of a CME and various digital resources and web pages; Know:BRCA evaluation: engaged HCPs in qualitative research efforts to learn more about their needs and utilization of resources related to hereditary breast and ovarian cancer (HBOC). FY15 Recommendation #5 is supported in part through various DCPC research projects (i.e. genomics, alcohol, etc. The Know: BRCA (formerly BodyTalk) clinical decision support tool was launched in 2014 to address issues of hereditary breast cancer among young women. The resource includes content that encourages health care providers and young women to engage in dialogue about breast cancer risk. The resource was evaluated and completed in FY18 for efficacy and utilization. As a result of the evaluation Know:BRCA/Body Talk was modified to address issues identified in the evaluation in FY20 and it will be relaunched to reflect the changes. Additional continued activities include funding grantees to support young breast cancer survivors and increase knowledge about breast cancer genetics and the use of the Know:BRCA clinical decision support tool. In FY20 a cooperative agreement was launched which focuses on supporting young breast cancer survivors including metastatic and underserved populations. The development of provider resources and patient navigation resources is also a part of this ongoing work which addresses FY15 Recommendation #9

**What is the approximate Percentage of these recommendations that have been or will be Partially implemented by the agency?**

8%

**% of Recommendations Partially Implemented Comments**

1 of 12 recommendations have been partially implemented. Work to complete the FY15

Recommendation #8 will continue. It is approximately 85% complete with expected completion in the next fiscal year. Efforts are underway to evaluate the effectiveness of the two health care provider CMEs. Additional questions will also be included in DocStyles to assist with this evaluation. 2 of 12 recommendation have not been implemented or considered at this time due to feasibility of proposed effort and funding availability. FY 15 Recommendation #7 may be considered in the future.

**Does the agency provide the committee with feedback regarding actions taken to implement recommendations or advice offered?**

Yes  No  Not Applicable

**Agency Feedback Comments**

CDC provides feedback to the Committee during formal public meetings.

**What other actions has the agency taken as a result of the committee's advice or recommendation?**

Checked if Applies

Reorganized Priorities	<input type="checkbox"/>
Reallocated resources	<input type="checkbox"/>
Issued new regulation	<input type="checkbox"/>
Proposed legislation	<input type="checkbox"/>
Approved grants or other payments	<input type="checkbox"/>
Other	<input checked="" type="checkbox"/>

**Action Comments**

CDC launched and completed formative research regarding the national public education campaign targeting young women and health care providers about early onset breast cancer and general breast health among young women. The public education campaign was also launched in May 2015 and is ongoing. Information can be found at [www.cdc.gov/bringyourbrave](http://www.cdc.gov/bringyourbrave).

**Is the Committee engaged in the review of applications for grants?**

No

**Grant Review Comments**

N/A

**How is access provided to the information for the Committee's documentation?**

Checked if Applies

- Contact DFO
- Online Agency Web Site
- Online Committee Web Site
- Online GSA FACA Web Site
- Publications
- Other

**Access Comments**

N/A